vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $112.4M, roughly 1.8× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 8.3%, a 25.2% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 9.0%). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
BY vs COLL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $205.4M |
| Net Profit | $37.6M | $17.0M |
| Gross Margin | — | 62.5% |
| Operating Margin | — | 29.6% |
| Net Margin | 33.4% | 8.3% |
| Revenue YoY | 9.0% | 12.9% |
| Net Profit YoY | 33.0% | 35.3% |
| EPS (diluted) | $0.83 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $205.4M | ||
| Q3 25 | $115.7M | $209.4M | ||
| Q2 25 | $110.5M | $188.0M | ||
| Q1 25 | $103.1M | $177.8M | ||
| Q4 24 | $104.7M | $181.9M | ||
| Q3 24 | $101.8M | $159.3M | ||
| Q2 24 | $99.4M | $145.3M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $17.0M | ||
| Q3 25 | $37.2M | $31.5M | ||
| Q2 25 | $30.1M | $12.0M | ||
| Q1 25 | $28.2M | $2.4M | ||
| Q4 24 | $30.3M | $12.5M | ||
| Q3 24 | $30.3M | $9.3M | ||
| Q2 24 | $29.7M | $19.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 62.5% | ||
| Q3 25 | — | 61.7% | ||
| Q2 25 | — | 57.7% | ||
| Q1 25 | — | 54.8% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 62.5% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 29.6% | ||
| Q3 25 | 43.1% | 29.7% | ||
| Q2 25 | 35.2% | 18.7% | ||
| Q1 25 | 36.4% | 12.2% | ||
| Q4 24 | 38.6% | 20.9% | ||
| Q3 24 | 39.3% | 21.9% | ||
| Q2 24 | 40.4% | 32.7% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 8.3% | ||
| Q3 25 | 32.1% | 15.0% | ||
| Q2 25 | 27.2% | 6.4% | ||
| Q1 25 | 27.4% | 1.4% | ||
| Q4 24 | 34.3% | 6.9% | ||
| Q3 24 | 29.8% | 5.9% | ||
| Q2 24 | 29.9% | 13.5% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.48 | ||
| Q3 25 | $0.82 | $0.84 | ||
| Q2 25 | $0.66 | $0.34 | ||
| Q1 25 | $0.64 | $0.07 | ||
| Q4 24 | $0.68 | $0.36 | ||
| Q3 24 | $0.69 | $0.27 | ||
| Q2 24 | $0.68 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $301.7M |
| Total Assets | $9.9B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $386.7M | ||
| Q3 25 | $259.0M | $285.9M | ||
| Q2 25 | $218.3M | $222.2M | ||
| Q1 25 | $421.3M | $197.8M | ||
| Q4 24 | $563.1M | $162.8M | ||
| Q3 24 | $452.6M | $120.0M | ||
| Q2 24 | $730.5M | $271.6M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $301.7M | ||
| Q3 25 | $1.2B | $274.8M | ||
| Q2 25 | $1.2B | $232.2M | ||
| Q1 25 | $1.1B | $234.4M | ||
| Q4 24 | $1.1B | $228.8M | ||
| Q3 24 | $1.1B | $234.3M | ||
| Q2 24 | $1.0B | $216.6M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $1.7B | ||
| Q3 25 | $9.8B | $1.6B | ||
| Q2 25 | $9.7B | $1.6B | ||
| Q1 25 | $9.6B | $1.6B | ||
| Q4 24 | $9.5B | $1.7B | ||
| Q3 24 | $9.4B | $1.6B | ||
| Q2 24 | $9.6B | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $123.0M |
| Free Cash FlowOCF − Capex | — | $122.4M |
| FCF MarginFCF / Revenue | — | 59.6% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $123.0M | ||
| Q3 25 | $38.3M | $78.4M | ||
| Q2 25 | $16.3M | $72.4M | ||
| Q1 25 | $27.1M | $55.4M | ||
| Q4 24 | $175.2M | $84.6M | ||
| Q3 24 | $19.8M | $-9.0M | ||
| Q2 24 | $40.1M | $67.4M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $122.4M | ||
| Q3 25 | $38.0M | $78.3M | ||
| Q2 25 | $15.2M | $72.4M | ||
| Q1 25 | $25.0M | $54.6M | ||
| Q4 24 | $171.2M | $84.1M | ||
| Q3 24 | $19.1M | $-9.2M | ||
| Q2 24 | $39.4M | $67.1M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 59.6% | ||
| Q3 25 | 32.8% | 37.4% | ||
| Q2 25 | 13.7% | 38.5% | ||
| Q1 25 | 24.3% | 30.7% | ||
| Q4 24 | 163.5% | 46.2% | ||
| Q3 24 | 18.8% | -5.8% | ||
| Q2 24 | 39.7% | 46.2% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.3% | ||
| Q3 25 | 0.3% | 0.1% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 2.0% | 0.4% | ||
| Q4 24 | 3.8% | 0.3% | ||
| Q3 24 | 0.6% | 0.2% | ||
| Q2 24 | 0.7% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 7.25× | ||
| Q3 25 | 1.03× | 2.49× | ||
| Q2 25 | 0.54× | 6.05× | ||
| Q1 25 | 0.96× | 22.92× | ||
| Q4 24 | 5.78× | 6.75× | ||
| Q3 24 | 0.65× | -0.96× | ||
| Q2 24 | 1.35× | 3.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
